

Lale S Tokg zo lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/689597/publications.pdf>

Version: 2024-02-01

94
papers

30,845
citations

66343

42
h-index

37204

96
g-index

104
all docs

104
docs citations

104
times ranked

24757
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal, 2022, 43, 830-833.	2.2	92
2	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology, 2022, 28, 2030-2037.	1.8	8
3	Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future. Atherosclerosis, 2022, 340, 51-52.	0.8	5
4	The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation. Neuromuscular Disorders, 2022, 32, 50-56.	0.6	8
5	The dawn of a new era of targeted lipid-lowering therapies. European Heart Journal, 2022, 43, 3198-3208.	2.2	48
6	The year in cardiovascular medicine 2021: dyslipidaemia. European Heart Journal, 2022, , .	2.2	9
7	Chasing LDL cholesterol to the bottom – PCSK9 in perspective. , 2022, 1, 554-561.		13
8	Association of dietary and gut microbiota-related metabolites with calcific aortic stenosis. Acta Cardiologica, 2021, 76, 544-552.	0.9	10
9	Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry. Cardiovascular Drugs and Therapy, 2021, 35, 801-808.	2.6	9
10	Should We Target Global Risk or Risk Factors?. Current Atherosclerosis Reports, 2021, 23, 2.	4.8	2
11	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.8	37
12	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. Atherosclerosis, 2021, 322, 77-81.	0.8	8
13	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.8	83
14	Redefining cardiovascular risk prediction: is the crystal ball clearer now?. European Heart Journal, 2021, 42, 2468-2471.	2.2	13
15	The landscape of preventive cardiology in Turkey: Challenges and successes. American Journal of Preventive Cardiology, 2021, 6, 100184.	3.0	14
16	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
17	Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis. Atherosclerosis Plus, 2021, 44, 18-18.	0.7	1
18	Familial Hypercholesterolemia: Global Burden and Approaches. Current Cardiology Reports, 2021, 23, 151.	2.9	38

#	ARTICLE	IF	CITATIONS
19	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
20	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	13.7	142
21	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2021, 338, 55-63.	0.8	8
22	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 401-411.	1.4	18
23	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 50-67.	11.4	114
24	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1630-1636.	1.8	23
25	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
26	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
27	Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 751-755.	1.5	14
28	In-hospital statin initiation characteristics and one-year statin adherence rates in patients hospitalised for acute coronary syndrome. <i>Acta Cardiologica</i> , 2020, 76, 1-7.	0.9	2
29	Can EPA evaporate plaques?. <i>European Heart Journal</i> , 2020, 41, 3933-3935.	2.2	6
30	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	3.7	4
31	Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2020, 14, 361-370.e2.	1.5	8
32	Evaluation of internal medicine physicians' attitudes toward the treatment of dyslipidemia. <i>Postgraduate Medicine</i> , 2020, 132, 538-543.	2.0	1
33	Diet, Lifestyle, Smoking. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	5
34	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5
35	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020, 42, e6-e8.	1.2	9
36	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776

#	ARTICLE	IF	CITATIONS
37	How Did The Updated Haemodynamic Definitions Affect The Frequency Of Pulmonary Hypertension In Patients With Systemic Sclerosis?. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 30-35.	0.9	1
38	An updated perspective and pooled analysis of Cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 61-76.	0.9	1
39	The new Dyslipidaemia Team of the <i>European Heart Journal</i>. <i>European Heart Journal</i> , 2020, 41, 3870-3871.	2.2	0
40	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 56.	30.5	1,601
41	PCSK9 inhibition and inflammation: A narrative review. <i>Atherosclerosis</i> , 2019, 288, 146-155.	0.8	80
42	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
43	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
44	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.8	227
45	Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2019, 13, 455-467.	1.5	26
46	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	1.8	558
47	Demographics of patients ≥ 80 years with heart failure who were admitted to the cardiology clinics in Turkey. <i>Anatolian Journal of Cardiology</i> , 2019, 21, 196-205.	0.9	1
48	Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 160-168.	0.9	6
49	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.5	86
50	A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). <i>Atherosclerosis</i> , 2018, 270, 42-48.	0.8	30
51	The challenge of risk prediction: How good are we?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 418-419.	1.8	4
52	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
53	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	2.2	13
54	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	2.2	171

#	ARTICLE	IF	CITATIONS
55	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
56	Reprint of: Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2980-2995.	2.8	17
57	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
58	What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?. <i>Atherosclerosis</i> , 2018, 277, 341-346.	0.8	15
59	Pulmonary hypertension in Takayasu arteritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1634-1639.	1.9	24
60	Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1141-1156.	2.8	272
61	Is there a gender gap in secondary prevention of coronary artery disease in Turkey?. <i>Türk Kardiyoloji Dernegi Arsivi</i> , 2018, 46, 683-691.	0.2	3
62	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	2.2	137
63	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
64	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	1.8	83
65	Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 17, 19-31.	1.2	3
66	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.8	1,189
67	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
68	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	26
69	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	1.8	772
70	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 209, 284-290.	1.7	77
71	Cost of heart failure management in Turkey: results of a Delphi Panel. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 554-562.	0.9	10
72	Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). <i>Türk Kardiyoloji Dernegi Arsivi</i> , 2016, 44, 53-64.	0.5	6

#	ARTICLE	IF	CITATIONS
73	Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 900-915.	0.9	6
74	Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. <i>Journal of Physical Therapy Science</i> , 2015, 27, 1309-1312.	0.6	21
75	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	2.2	1,024
76	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	6.8	101
77	Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidenceâ€Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	79
78	Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels. <i>American Journal of Cardiology</i> , 2015, 115, 647-651.	1.6	54
79	EdÃ±torÃ±al. <i>Anatolian Journal of Cardiology</i> , 2015, 15, XII.	0.9	0
80	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
81	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
82	Implementation, target population, compliance and barriers to risk guided therapy. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 37-41.	1.8	7
83	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
84	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
85	The association between circulating endothelial progenitor cells and coronary collateral formation. <i>Atherosclerosis</i> , 2011, 219, 851-854.	0.8	19
86	Successful pregnancy by in vitro fertilization after Mustard operation for transposition of the great arteries. <i>Journal of Cardiology Cases</i> , 2011, 3, e50-e52.	0.5	0
87	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
88	Atherosclerotic Vascular Disease and Risk Factors in Turkey: From Past to Present. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 286-291.	2.0	16
89	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 0.8 BT /Over	2.2	1,392
90	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.8 BT /Over	2.2	1,392

#	ARTICLE	IF	CITATIONS
91	Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. Journal of Heart Valve Disease, 2006, 15, 671-8.	0.5	1
92	Which patients have the highest cardiovascular risk? A follow-up study from Turkey. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 250-256.	2.8	0
93	Plasma interleukin-6 levels are increased in coronary artery ectasia. Acta Cardiologica, 2004, 59, 515-519.	0.9	53
94	Atrial Fibrillation After Coronary Artery Bypass Surgery: Predictors and the Role of MgSO ₄ Replacement. Journal of Cardiac Surgery, 1996, 11, 421-427.	0.7	56